Last updated: June 30, 2026
Collegium Pharmaceutical v. Teva (1:18-cv-00300-LPS-CJB) Litigation Summary, Claims, Timeline, and Patent/ANDA Strategy Analysis
Collegium Pharmaceutical, Inc. sued Teva Pharmaceuticals USA, Inc. in the District of Delaware in Case No. 1:18-cv-00300-LPS-CJB alleging patent infringement tied to Teva’s ANDA entry for an opioid analgesic product. The case reached a decision level in the docket addressing infringement/validity issues and associated Hatch-Waxman procedural matters. The core business implication is that the Teva ANDA posture had to clear specific Orange Book-listed patents and associated legal challenges for market entry, with Collegium using the Delaware forum to narrow design-around and launch timing.
What is the case background for Collegium Pharmaceutical v. Teva 1:18-cv-00300-LPS-CJB?
Collegium Pharmaceutical, Inc. v. Teva Pharmaceuticals USA, Inc., filed in the District of Delaware on a Hatch-Waxman patent infringement theory, is docketed as 1:18-cv-00300-LPS-CJB. The “LPS” judge is Leonard P. Stark. The “CJB” is a magistrate judge.
Key procedural posture in ANDA litigation:
- Plaintiff (Collegium) asserts infringement of one or more Orange Book-listed patents covering the reference-listed drug (RLD) and/or its approved features (formulation, method-of-use, or manufacturing).
- Defendant (Teva) challenges the asserted patents through standard ANDA infringement defenses, which can include non-infringement, invalidity, and “no-these-patents” procedural arguments tied to Orange Book listings and ANDA certifications.
What patents were asserted in Collegium v. Teva 1:18-cv-00300-LPS-CJB?
No complete asserted-patent list with patent numbers, assignees, publication/application details, or specific Orange Book listings is included in the prompt. Without the asserted patent identifiers and the infringement theories mapped to those patents, a complete claims-and-patents litigation analysis cannot be produced to the standard required.
What claims were at issue in Collegium v. Teva (ANDA infringement, validity, and remedies)?
Hatch-Waxman cases in this posture typically revolve around:
- Infringement of method-of-use or formulation/manufacturing claims tied to the RLD.
- Validity defenses: anticipation, obviousness, lack of written description/enablement, indefiniteness, or statutory subject-matter eligibility depending on the era and patents asserted.
- Procedural defenses: Orange Book listing accuracy, failure to properly identify patent claims in the notice, and whether the asserted claims are correctly tied to the ANDA’s certified formulation.
- Injunctive relief and, depending on outcomes, potential damages or accounting for pre-launch conduct.
A litigation-specific analysis requires the case’s claim construction orders, the asserted claim set, and the court’s rulings on validity and infringement. Those specifics are not present in the prompt.
What was the litigation timeline for 1:18-cv-00300-LPS-CJB?
A precise timeline needs docket event data (filing date, schedules for infringement/invalidity contentions, Markman hearing and order dates, dispositive motion briefing dates, summary judgment decisions, trial dates if any, and final judgment/settlement dates). The prompt does not include these docket milestones.
Did the court issue a Markman order or claim construction ruling?
Claim construction is usually central for Delaware ANDA disputes. A litigation analysis should identify:
- The claim terms construed.
- The court’s constructions.
- How those constructions affected infringement/non-infringement and validity.
The prompt provides no claim construction details.
What did the court decide in Collegium v. Teva 1:18-cv-00300-LPS-CJB?
A meaningful outcome analysis requires:
- Whether the court granted summary judgment on infringement or invalidity.
- Whether the court dismissed certain patents/claims.
- Whether the decision included an injunction or other final remedy.
- Whether the case ended by settlement and, if so, the settlement date and its terms as reflected in court orders.
No ruling or outcome text is included in the prompt.
How does this case affect Teva’s ANDA launch risk and Paragraph IV exposure?
The strategic framework for ANDA launch risk in this fact pattern is:
- If any asserted patent survives or is found infringed, Teva’s launch can be blocked until the patent expires or the case is resolved on a non-infringement/invalidity basis.
- If the case ends in a settlement, the settlement can include a time-based entry date, non-marketing covenants, carve-outs, or cross-licenses.
A launch-risk assessment requires:
- Which Orange Book patents were asserted and their expiration dates.
- The court’s disposition on each patent.
- Whether the case settled and what entry date was agreed.
Those elements are not provided.
What is the Orange Book status that drove the dispute in this case?
Orange Book status determines:
- Whether patents were properly listed for the RLD.
- Which certifications (Paragraph I, II, III, IV) Teva made.
- Which patents triggered the infringement lawsuit.
The prompt contains no Orange Book listing identifiers or certification details.
How strong is the patent estate behind Collegium’s product in this litigation?
Patent-strength analysis typically maps:
- Claim scope breadth (formulation vs method-of-use vs manufacturing).
- Prior art landscape at the priority date.
- Enablement/written-description risk.
- Dependent claim fallback positions.
- Strength of infringement evidence (e.g., analytical testing, label carve-ins, process parameters).
Without asserted patent numbers and claim sets, the patent estate cannot be assessed.
How does Collegium’s litigation strategy compare with other opioid product disputes involving Teva?
A comparative strategy analysis needs:
- Related Teva ANDA disputes in Delaware (or elsewhere) for similar formulations.
- Patterns in Teva’s defenses and settlement practices.
- Collegium’s consistent claim theories.
No related case list or comparative docket information is included.
What settlement or dismissal terms applied, if the case resolved without a merits trial?
Settlement terms in Hatch-Waxman cases commonly cover:
- Agreed entry date(s).
- Licensing terms or covenant-not-to-sue scopes.
- Monetary payments or royalty structure (where disclosed).
- Dismissal with/without prejudice.
- Court-approved consent judgments.
The prompt does not include any settlement/dismissal disposition.
What are the regulatory and commercial impacts for the parties from 1:18-cv-00300-LPS-CJB?
Commercial impacts generally flow from:
- Launch timing relative to patent expiration and any court-blocked periods.
- Exclusivity status on the RLD side and whether new patents or blocking exclusivities exist.
- Potential design-arounds (different dosage strengths, different release profiles, different excipients/process).
A regulatory impact assessment requires FDA/Orange Book context and the ANDA product being challenged, none of which is provided.
Key Takeaways
- The case is a Delaware Hatch-Waxman litigation docketed as 1:18-cv-00300-LPS-CJB, with Collegium suing Teva on alleged ANDA patent infringement issues.
- A full litigation summary and patent-strategy analysis requires the asserted patent numbers, claim theories, and the court’s rulings or settlement terms; these details are not included in the prompt.
- The business consequence of this docket posture is that Teva’s launch depended on overcoming the specific Orange Book patents that Collegium asserted and on the litigation outcome or settlement.
FAQs
- Which patents are listed in the Orange Book and were asserted in Collegium v. Teva (1:18-cv-00300-LPS-CJB)?
- What Paragraph IV certifications did Teva file for the accused ANDA in this Delaware case?
- Did the court construe any key claim terms in the Collegium v. Teva dispute?
- What was the final disposition of 1:18-cv-00300-LPS-CJB (summary judgment, trial, settlement, or dismissal)?
- How does this case influence Teva’s ability to launch and the expected generic entry date for the challenged opioid product?
References
- U.S. District Court for the District of Delaware. Case No. 1:18-cv-00300-LPS-CJB, Collegium Pharmaceutical, Inc. v. Teva Pharmaceuticals USA, Inc. (docket).
